Cargando…
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Autores principales: | Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699912/ https://www.ncbi.nlm.nih.gov/pubmed/34941969 http://dx.doi.org/10.1371/journal.pone.0261994 |
Ejemplares similares
-
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2022) -
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Seiwert, Tanguy, et al.
Publicado: (2012) -
Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Publicado: (2022) -
Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
por: Kogata, Yuhei, et al.
Publicado: (2018) -
Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
por: Chen, Hsiu-Mei, et al.
Publicado: (2015)